Open AccessP966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME‐ THE MAYO CLINIC EXPERIENCE
Author(s) -
Vaxman I.,
Kumar S.,
buadi F.,
Lacy M.,
Dingli D.,
Fonder A.,
Hobbs M.,
Hayman S.,
hwa L. Y.,
Kouralis T.,
Warsame R.,
Muchtar E.,
Nelson L.,
Kapoor P.,
Grogan M.,
Go R.,
Gonsalves W.,
Siddiqi M.,
Robert K.,
Rajkumar V.,
Gertz M.,
Dispenzieri A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846732.06415.be
Subject(s) - medicine , poems syndrome , pomalidomide , daratumumab , carfilzomib , lenalidomide , organomegaly , polyneuropathy , oncology , multiple myeloma